

**JUBILANT PHARMA LIMITED**  
(Company Registration No. 200506887H)  
(Incorporated in the Republic of Singapore)  
Registered office: 80 Robinson Road, #02-00, Singapore 068898

**ANNOUNCEMENT**

**Jubilant Pharma Limited to partially redeem 4.875% Senior Notes Due 2021**  
**ISIN Number: XS1493722299**  
**Common Code: 149372229**

December 30, 2020

**Singapore Exchange Securities Trading Limited**

11 North Buona Vista Drive #06-07  
The Metropolis Tower 2  
Singapore 138589

Dear Sirs,

Jubilant Pharma Limited (the “**Company**”) wishes to announce that it has given notice to the holders of its US\$300,000,000 4.875% Senior Notes due 2021 (the “**Notes**”) that it has elected to exercise its option to redeem US\$100,000,000 in aggregate principal amount of the Notes on January 29, 2021 (the “**Redemption Date**”) pursuant to the terms of the indenture dated as of October 6, 2016 (the “**Indenture**”) between the Company and The Bank of New York Mellon, London Branch as trustee, governing the Notes. The Company had made the first early redemption of US\$100,000,000 in November 2019 and the outstanding amount of the Notes after the proposed redemption of January 29, 2021 would be US\$100,000,000.

Pursuant to the terms of the Indenture, the redemption price for the Notes will be equal to 101.21875% of the principal amount of such Notes, plus accrued and unpaid interest thereon, to (but not including) the Redemption Date (the “**Redemption Price**”). The Notes will be redeemed on a *pro rata* basis and the payment of the Redemption Price in respect of the Notes called for redemption will occur via the standard procedures of Euroclear and Clearstream. The Notes called for redemption will be cancelled by the Company upon redemption.

Thanking you,

Yours faithfully,

For Jubilant Pharma Limited

Sd/-

Shyam S. Bhartia  
Chairman and Managing Director